Sarepta Therapeutics, Inc.
Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapies for rare diseases. They offer several treatments for Duchenne muscular dystrophy (DMD), including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS. The company is also developing SRP-5051 and SRP-9003 for DMD.
Overview
Strengths
- Consistent growth: revenue has compounded at 32.4% a year over 5 years, rising every year.
- Paying down debt: long-term debt fell by 3.9 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 6.7% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Unstable profitability: operating margin ranged from -104% to 11% over the last 6 years, with operating losses in 5 of them.
Key Financial Data